The most recent WHO classification for lung adenocarcinoma is based on the predominant histologic subtype in the resected tumor. Several studies have validated the use of this classification system for prognostic purposes, but predicting response to adjuvant chemotherapy has not yet been tested.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung Cancer - Chemotherapy
May 8, 2015
Targeting specific genetic changes in cancer cells offers patients personalized therapy for their tumors. The number of identified abnormalities is rapidly increasing, and determining whether they represent driver mutations or background noise is increasingly difficult. The IBM Watson supercomputer will be used by 10 US cancer centers to identify a
February 16, 2015
Usually patients with prior cancer are excluded in lung cancer trials, but the impact on survival in lung cancer is not known. In a cohort of 102929 patients older than 65 with stage IV lung cancer, a propensity score analysis were performed and found that patients with prior cancer had better survival (all-cause and lung cancer-specific).
February 3, 2015
This consensus statement from the European Neuroendocrine Society is based on extensive bibliographic searches and systematic review. Surgery is the mainstay of therapy for most tumors, and includes resection of metastases when this can be accomplished in a curative manner. Somatostatin analogues are considered first line therapy for unresectable c
February 2, 2015
The authors queried the National Cancer Data Base to assess outcomes of patients with R1 resection margins related to the presence and type of postoperative adjuvant therapy. 3.1% of over 54,000 resections had R1 margins, which negatively affected long-term survival. Combined chemotherapy and radiation therapy improved outcomes; administration of c
November 11, 2014
This study explored financial conflicts of interest (FCOI) among authors of published guidelines and consensus statements and their relationship to endorsement of specific drugs. 93% of recent articles reported FCOI status. Of articles publishing funding sources, 65% reported partial or full industry funding. Endorsement of chemotherapeutic agents
May 21, 2014
This study evaluated over 200 RTCs of systemic therapy for NSCLC. There has been a steady increase in the number of trials reporting outcomes for progression-free survival. Over 50% of trials now report a positive outcome without meeting the primary endpoint of the trial. Although the sample size of the trials is increasing, the magnitude of repor
May 3, 2014
This systematic review and meta-analysis of individual patient data from 15 RCTs (2385 pts) assessed the utility of preoperative chemotherapy in patients with primarily stages Ib-IIIa NSCLC. Chemotherapy resulted in a 13% reduction in death (HR 0.87, p=0.007), and a 5% survival improvement at 5 years.
Pages
- « first
- ‹ previous
- 1
- 2
- 3